Headline: Bavarian Nordic Grants Exclusive Chikungunya Vaccine Distribution Rights to Eurofarma

Bavarian Nordic A/S (NASDAQ: BAVA) announced on January 23, 2026, that it has granted exclusive distribution rights for its chikungunya vaccine to Eurofarma, a Brazilian pharmaceutical company. The agreement covers Latin American markets, excluding Brazil, where Eurofarma retains existing rights. Financial terms were not disclosed. This partnership aims to expand access to the vaccine, which is currently in late-stage clinical trials. Shares of Bavarian Nordic closed unchanged at $15.20 on the day of the announcement.